Drug Benefit List

Drug Manufacturer Submission Deadlines

IMPORTANT SUBMISSION INFORMATION
July 2017

The following information provides details on effective dates and deadlines for submitting Drug Product submissions to the Alberta Drug Benefit List (ADBL) for 2017 - 2018.

The following dates may be subject to change; however, you will be notified accordingly if such a change occurs.

Deadlines for Expedited Reviews of Interchangeable Drug Products
ADBL Effective Date Deadlines for Complete Submissions
September 1, 2017 July 25, 2017
October 1, 2017 August 25, 2017
November 1, 2017 September 25, 2017
December 1, 2017 October 25, 2017
February 1, 2018 November 30, 2017
March 1, 2018 January 25, 2018
May 1, 2018 March 26, 2018
June 1, 2018 April 25, 2018
July 1, 2018 May 25, 2018
August 1, 2018 June 25, 2018
September 1, 2018 July 25, 2018
October 1, 2018 August 24, 2018
Deadlines for all other Drug Product Submission Categories
ADBL Effective Date Deadlines for Complete Submissions
September 1, 2017 June 12, 2017
November 1, 2017 August 10, 2017
February 1, 2018 October 10, 2017
March 1, 2018 December 11, 2017
May 1, 2018 February 9, 2018
July 1, 2018 April 10, 2018
September 1, 2018 June 11, 2018
November 1, 2018 August 10, 2018

Manufacturers should note that only complete submissions, satisfying all the submission requirements of the applicable category of Drug Product received by 4:30 p.m. Mountain Standard / Daylight Savings Time (as applicable) on the deadline, will be put forward for consideration by the Expert Committee on Drug Evaluation and Therapeutics or Expedited Review, as applicable. There is no guarantee that every completed submission will be reviewed and/or a recommendation made at the next scheduled meeting of the Expert Committee.

Alberta Price Confirmation Tentative Dates

The Alberta Price Confirmation (APC) is issued prior to an ADBL publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.

ADBL Effective Date APC Tentative Issue Date
December 1, 2017 November 2, 2017
February 1, 2018 January 4, 2018
March 1, 2018 February 2, 2018
April 1, 2018 February 15, 2018
May 1, 2018 April 5, 2018
June 1, 2018 May 3, 2018
July 1, 2018 June 5, 2018
August 1, 2018 July 4, 2018
September 1, 2018 August 2, 2018
October 1, 2018 September 4, 2018
November 1, 2018 October 3, 2018
December 1, 2018 November 2, 2018

Correspondence

Manufacturers may provide submissions for consideration for potential addition to the Alberta Drug Benefit List (ADBL) via email to the following address: submissions@ab.bluecross.ca

Submissions sent to other email addresses will not be considered for potential addition to the ADBL. It is recommended that manufacturers place the drug name(s) and strength(s) of the submitted product(s) in the subject header in order to ensure that multiple emails can be easily associated with one another.

Manufacturers are reminded that hard copies of submissions must follow by mail and should be sent to the attention of:

Manager
Scientific and Research Services
Alberta Blue Cross
10009 – 108 Street NW
Edmonton AB T5J 3C5

A copy of covering correspondence and summary documents only should be forwarded to:

Executive Director
Pharmaceutical Funding and Guidance
Alberta Health
11th Floor, 10025 Jasper Avenue
Edmonton AB T5J 1S6

Questions or Comments

Questions or comments regarding the drug review process or submission deadlines can be addressed to:

Coordinator
Scientific and Research Services
Alberta Blue Cross
10009 – 108 Street NW
Edmonton AB T5J 3C5
Phone: (780) 498-8098
Fax: (780) 498-3534
Email: submissions@ab.bluecross.ca

 


NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.